We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Approximately 60% to 85% of patients who develop ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

"For many patients, having a subcutaneous induction option is an important step forward—offering the flexibility of at-home administration after proper training without compromising efficacy," said ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE registry ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Three new IL-23 inhibitors have been approved for IBD, ...

Developed by Janssen, TREMFYA ® is a human monoclonal antibody against the p19 subunit of interleukin (IL)-23, and is approved in the U.S., Canada, the European Union, Japan and a number of other ...

*The as observed analysis set included participants who entered the LTE, received ≥1 partial or complete study drug dose during the LTE, remained on treatment, and had data available at Week 96; ...

PARIS — Doses of interleukin (IL)-17 and IL-23 inhibitors were safely reduced in people with plaque psoriasis who had “very stable low disease activity”; it was reported during a late-breaking news ...

Furthermore, in prespecified analyses of subpopulations defined by prior advanced therapy treatment status, TREMFYA® demonstrated clinically meaningful results across all endpoints in both biologic ...